Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171605 | 1.00 | SLC18A3 (0.47) | SLC18A3KDM4EALDH1A1AKR1C3AKR1C1 | |
| SCHEMBL600742 | 0.88 | ESR2 (0.49) | — | |
| SCHEMBL4975063 | 0.86 | IDO1 (0.48) | DRD2PRCP | |
| SCHEMBL3900477 | 0.86 | IDO1 (0.48) | DRD2PRCP | |
| SCHEMBL5368277 | 0.84 | AKR1C3 (0.44) | SLC18A3KDM4EALDH1A1AKR1C3AKR1C1 | |
| Hydrochloric Acid SCHEMBL5374122 | 0.83 | AKR1C3 (0.42) | SLC18A3KDM4EALDH1A1AKR1C3AKR1C1 | |
| SCHEMBL5967397 | 0.80 | — | — | |
| SCHEMBL6270743 | 0.80 | — | — | |
| SCHEMBL17730076 | 0.79 | PSMB5 (0.42) | KDM4EALDH1A1AKR1C3NPC1RAB9A | |
| SCHEMBL20838768 | 0.78 | KCNH2 (0.48) | SLC18A3KDM4EALDH1A1AKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7339065-B2 | Design and synthesis of optimized ligands for PPAR | BETHESDA PHARMACEUTICALS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070099969-A1 | Design and synthesis of optimized ligands for ppar | THE UNIVERSITY OF MISSISSIPPI | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099969-A1 | Design and synthesis of optimized ligands for ppar | PPARD, PPARA, PPARG | SLC18A3 4741/4885KDM4E 697/4885ALDH1A1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.